Table 1 Patient demographics and disease characteristics
Number (%)c or mean (SD) or median (IQR 25–75) (n = 1846 patients) | |
|---|---|
Country | |
Australia | 240 (13.00 %) |
China | 235 (12.73 %) |
Hong Kong | 190 (10.29 %) |
Indonesia | 98 (5.31 %) |
Malaysia | 193 (10.46 %) |
Philippines | 124 (6.72 %) |
Singapore | 221 (11.97 %) |
Taiwan | 295 (15.98 %) |
Thailand | 250 (13.54 %) |
Ethnicity | |
Caucasian | 126 (6.73 %) |
Chinese | 1008 (54.60 %) |
Filipino | 132 (7.15 %) |
Indonesian | 102 (5.53 %) |
Thai | 255 (13.81 %) |
Malay | 98 (5.31 %) |
Vietnamese/Cambodian | 24 (1.30 %) |
Indian/Sri Lankan | 64 (3.47 %) |
Othera | 37 (2.00 %) |
Female gender | 1723 (93.34 %) |
Age at diagnosis (years) | 29.34 (12.35) |
Age at diagnosis ≤30 years | 973 (52.71 %) |
Disease duration at enrollment (years) | 8.64 (8.50) |
Disease duration at enrollment ≤1 year | 149 (8.07 %) |
Current smoker | 67 (3.63 %) |
First-degree relative with SLE | 117 (6.34 %) |
Highest attained education level | |
Primary | 242 (13.11 %) |
Secondary | 572 (30.99 %) |
Tertiary | 618 (33.48 %) |
ACR criteriab | |
Malar rash | 1087 (58.88 %) |
Discoid rash | 290 (15.71 %) |
Photosensitivity | 537 (29.09 %) |
Mouth ulcers | 670 (36.29 %) |
Arthritis | 1205 (65.28 %) |
Serositis | 313 (16.96 %) |
Renal | 803 (43.50 %) |
Neurologic | 160 (8.67 %) |
Haematologic | 1118 (60.56 %) |
Immunologic | 1547 (83.80 %) |
ANA | 1627 (88.14 %) |
Number of ACR criteria for SLE | 5.07 (1.39) |
Number of SLICC criteria for SLE | 5.70 (2.47) |
SLICC-DI score at enrollment | 0 (0–1) |
Damage present at enrollmentd | 694 (37.59 %) |
PGA at enrollment | 0.6 (0.3–1) |
Mild flare since last clinical review | 210 (11.38 %) |
Severe flare since last clinical review | 111 (5.94 %) |
SLEDAI-2 K score | 4 (2–6) |
SLEDAI-2 K no complement or dsDNA | 0 (0–4) |